AETE 2023 topbar

Antibody Engineering & Therapeutics 2023

Marriott Marquis San Diego | December 13th - 16th, 2023

GenScript is thrilled to announce our participation in the upcoming Antibody Engineering & Therapeutics 2023, which will be held at Marriott Marquis San Diego, from December 13th to 16th, 2023.

This conference is the #1 antibody engineering conference for accelerating next generation antibodies to commercial success. Over the course of this four-day gathering, attendees will have the opportunity to fully engage in workshops and presentations, gaining access to cutting-edge scientific research and insights on antibody engineering, design, and selection. The agenda covers pivotal subjects including Antibody Therapy, Bi-Specifics, Antibody Fragments, VHH, and a host of other topics essential to the industry's advancement.

Intrigued? Join GenScript and visit our Booth at #310!

GenScript x GenScript ProBio Presentations and Posters

Presentations

Topic 1: Applying high throughput novel pairing technology to discover diverse native antibodies from bulk B cells

Date: December 14, 2023 | Time: 12:15 - 12:45 PM PST

Dr. Gladys Keitany

Associate Director, BCR/Antibody Discovery, Adaptive Biotechnologies

Read More >>

Bio: 

Gladys Keitany, PhD, is an immunologist with over 15 years of experience and an expert in B cell Biology and antibody discovery. Her role at adaptive has associate director of antibody discovery is focused on identifying rare highly potent antibodies to both infectious diseases and autoimmune diseases using adaptive high throughput pairseg technology.  Gladys earned her PhD in pathobiology and parasitology from University of Washington in Seattle, WA, working on identifying vaccine candidates in malaria. She later did her postdoc on development of antigen specific B cells and impact of drug treatment in the liver stage of malaria parasite.

Abstract:

Immune receptors have become increasingly important modalities for therapeutic drug development with the advancement of antibody therapeutics over the last 30 years—and the more recent breakthrough in T-cell therapies. Therapeutic discovery approaches often involve the need for specialized animal models, such as humanized mice or other systems such as phage display, which require further engineering for desired therapeutic effects and reduction of immunogenicity. Here we present a next generation sequencing (NGS) platform for the discovery of novel, optimized therapeutics utilizing fully human immune repertoires for discovery, thus mitigating some of the needs for additional preclinical development. This talk will focus on our antibody discovery platform in infectious disease as a tool for therapeutic discovery. TruABTM Discovery is a novel approach integrating cellular immunology, high- throughput immunosequencing, bioinformatics and computational biology in order to discover naturally occurring human antibodies for prophylactic or therapeutic use. We adapted our previously described pairSEQTM technology to pair B-cell receptor heavy and light chains of antibodies derived from enriched antigen-specific memory B cells and bulk antibody secreting cells. This approach can accelerate discovery of diverse, multifunctional antibodies against any target of interest.

Topic 2: Robust production of antibody fragments and their therapeutic applications

Date: December 14, 2023 | Time: 12:45 - 1:15 PM PST

Dr. Liew Heng Tai

Senior Scientist, GenScript USA Inc

Read More >>

Bio: 

Liew Heng Tai is a senior scientist from GenScript with a passion for advancing protein and antibody production knowledge and procedures that meet industrial standards. He specializes in tackling complex and challenging projects by leveraging his expertise to overcome obstacles in the production of mAb, bsAb, antibody fragments, and other difficult-to-express proteins. Apart from providing technical solutions to the production teams, he also provides guidance with strong troubleshooting skills on difficult projects.

From Nanyang Technological University in Singapore, Heng Tai acquired his Doctor of Philosophy in Biological Sciences. From a sophisticated pathway in Alzheimer disease to ligase engineering, with a commitment to pushing the boundaries of what’s possible, he thrives on exploring the frontiers of science and contributing to breakthrough discoveries.

Abstract:

Antibody fragments have been developed as an alternative platform to full-size IgGs due to their size, tissue penetration capabilities, and manufacturing strategy. Therefore, developing a robust platform to produce antibody fragments is important to accelerate their development. We have developed a robust expression and purification platform that starts with antibody fragment gene synthesis, transfection, purification, and high QC standards to meet industry standards. Here, we will also cover their therapeutic applications and compare the pros and cons of different production platforms.

Topic 3: Accelerating Chimeric Antigen Receptor Discovery: From Targets to Leads with ProCARTM Platform

Date: December 14, 2023 | Time: 1:15 - 1:45 PM PST

Dr. Yu Liang

Vice President, R&D, GenScript ProBio USA

Read More >>

Bio: 

Dr. Yu Liang has over 20 years of research experience spanning academia and industry. He currently serves as VP for R&D at GenScript ProBio. Previously, he was a PI at Novartis and WuXi Biologics. His broad expertise covers cellular/molecular biology, virology, immunology, and early drug discovery of antibody therapeutics. He received his PhD in Virology/Microbiology from the University of Chicago and completed his postdoctoral training at NIH.

From Nanyang Technological University in Singapore, Heng Tai acquired his Doctor of Philosophy in Biological Sciences. From a sophisticated pathway in Alzheimer disease to ligase engineering, with a commitment to pushing the boundaries of what’s possible, he thrives on exploring the frontiers of science and contributing to breakthrough discoveries.

Abstract:

The talk will explore approaches to speed up the discovery of chimeric antigen receptor (CAR), including methods for identifying tumor-associated antigen (TAA) antibodies in formats like single domain antibodies (VHHs) or single chain variable fragments (scFvs). It will also discuss proof-of-concept testing of CAR leads using in vivo assays and animal models. Attendees will gain insights into cutting-edge technologies to optimize CAR design, and enhanced functionality leading to improved expression, reduced toxicities, and improved efficacy.

Topic 4: The Future of Plasmid Maxi-prep is here: AmMag™ Quatro Automated Solution

Date: December 15, 2023 | Time: 12:05 - 12:35 PM PST

Rouba Najjar, MBA

Head of Product Marketing, GenScript Product Division

Read More >>

Bio: 

Rouba Najjar is the Head of Product Marketing at GenScript Biotech. With over a decade of experience, she specializes in delivering automated solutions that streamline research and development processes. In her roles as Product Manager at Hamilton Robotics, Automation Team Lead at Baylor College of Medicine, and presently as the Head of Product Marketing at GenScript Biotech, she has consistently centered her work on delivering automated solutions and advanced tools. With a strong passion for automating processes to enhance research outcomes, her team excels in creating innovative, dependable, and high-quality reagents and instruments that cater to a diverse range of life science research and development domains.

From Nanyang Technological University in Singapore, Heng Tai acquired his Doctor of Philosophy in Biological Sciences. From a sophisticated pathway in Alzheimer disease to ligase engineering, with a commitment to pushing the boundaries of what’s possible, he thrives on exploring the frontiers of science and contributing to breakthrough discoveries.

Abstract:

Plasmid DNA (pDNA) plays a pivotal role in biotech applications such as protein expression and gene therapy. Large-scale pDNA purification (maxi-prep) is time consuming and labor-intensive. GenScript's AmMag™ Quatro offers an automated modular solution, allowing up to 24 maxi-prep samples to be processed with four modules, each handling up to 6 samples. Scientists can efficiently streamline high-quality plasmid purification, yielding transfection-grade pDNA.

Posters

Topic: AmMag™ Quatro Automated Plasmid Purification Made Easy

Rouba Najjar

Head of Product Marketing, GenScript Product Division

Topic: Empowering Antibody Drug Development

Amanda Grimm

Sr. Segment Marketing Manager, GenScript USA Inc

Topic: Leveraging mRNA Immunization to Develop Antibodies against Membrane Proteins

Huifoon Tan

Sr. Global Product Manager, GenScript USA Inc

Topic: Utilization of naïve VHH phage display library & integrated antibody engineering platform to generate antibody leads for CAR-T therapy

Yu Liang

Vice President, R&D, GenScript ProBio USA

Do you like the current new website?

Hate

Dislike

Neutral

Like

Love

*